Cargando…
Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of Ex Vivo Lentiviral Vector-Transduced Hematopoietic Stem and Progenitor Cells
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive lysosomal disease caused by deficiency of iduronate-2-sulfatase (IDS). The absence of IDS results in the accumulation of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. Currently, the only approved t...
Autores principales: | Smith, Miles C., Belur, Lalitha R., Karlen, Andrea D., Erlanson, Olivia, Podetz-Pedersen, Kelly M., McKenzie, Jessica, Detellis, Jenn, Gagnidze, Khatuna, Parsons, Geoffrey, Robinson, Nicholas, Labarre, Shelby, Shah, Saumil, Furcich, Justin, Lund, Troy C., Tsai, Hsing-Chen, McIvor, R. Scott, Bonner, Melissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808798/ https://www.ncbi.nlm.nih.gov/pubmed/36226412 http://dx.doi.org/10.1089/hum.2022.141 |
Ejemplares similares
-
Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10
por: Belur, Lalitha R., et al.
Publicado: (2020) -
Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome
por: Laoharawee, Kanut, et al.
Publicado: (2023) -
Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I
por: Belur, Lalitha R., et al.
Publicado: (2021) -
Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System
por: Belur, Lalitha R, et al.
Publicado: (2011) -
Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II
por: Catalano, Fabio, et al.
Publicado: (2023)